Misonix to Participate at Upcoming Craig-Hallum and Canaccord Genuity Investor Conferences

Rhea-AI Summary

Misonix, Inc. (NASDAQ: MSON) announced its participation in the Craig-Hallum 11th Annual Alpha Select Conference and the Canaccord Genuity Virtual MedTech & Diagnostics Forum in November 2020. CEO Stavros Vizirgianakis and CFO Joe Dwyer will host one-on-one meetings with investors at these events. The Craig-Hallum conference is set for November 17, 2020, while the Canaccord Genuity forum will occur on November 19, 2020. Misonix specializes in minimally invasive ultrasonic medical devices and regenerative products that enhance clinical outcomes.

FARMINGDALE, N.Y., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the upcoming Craig-Hallum and Canaccord Genuity investor conferences in November. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Chief Financial Officer, will be available to host one-on-one meetings with investors who are registered to attend the conferences.

• Craig-Hallum 11^thAnnual Alpha Select Conference
  Date: Tuesday, November 17^th

• Canaccord Genuity Virtual MedTech & Diagnostics Forum
  Date: Thursday, November 19^th

For more information about the conferences or to schedule a virtual one-on-one meeting with management, please contact your conference representative. Alternatively, please contact Misonix’s investor relations firm, JCIR, at mson@jcir.com.

About Misonix, Inc.
Misonix, Inc. (Nasdaq: MSON) is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients. Additional information is available on the Company's web site at www.misonix.com.

Contact:
Joe Dwyer	Norberto Aja, Jennifer Neuman
Chief Financial Officer	JCIR
Misonix, Inc.	212-835-8500 or mson@jcir.com
631-927-9113

FAQ

What are the upcoming conferences Misonix is participating in?

Misonix is participating in the Craig-Hallum 11th Annual Alpha Select Conference on November 17, 2020, and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020.

Who from Misonix will be available for one-on-one meetings?

CEO Stavros Vizirgianakis and CFO Joe Dwyer will be available for one-on-one meetings with investors.

How can investors schedule a meeting with Misonix's management?

Investors can contact their conference representative or Misonix’s investor relations firm, JCIR, at mson@jcir.com.

What is Misonix's focus in the medical device market?

Misonix focuses on providing minimally invasive therapeutic ultrasonic medical devices and regenerative products that improve clinical outcomes.

When will Misonix hold its meetings during the conferences?

Misonix will hold its meetings during the Craig-Hallum conference on November 17, 2020, and the Canaccord Genuity forum on November 19, 2020.